Piribedil is a nonergot selective D2/D3 agonist with significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes, which has shown efficacy in PD. It is available in some countries. The medication is orally administered once daily, typically at 150 mg (17-20). A 12-month, multicenter controlled study demonstrated similar efficacy between 150 mg of piribedil and 25 mg of bromocriptine as adjunctive therapy (17). Piribedil patients required less levodopa dose increase than those on bromocriptine. Intravenous administration of piribedil has also been reported (21).
Was this article helpful?